Gutniak, Mark

Antidiabetogenic effect of glucagon-like peptide-1 (7–36)amide in normal subjects and patients with diabetes mellitus

Gutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 868

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease

Nyström, T., Gutniak, M. K., Zhang, Q., Zhang, F., Holst, J. J., Ahrén, B., & Sjöholm, Å. (2004) · American Journal of Physiology-Endocrinology and Metabolism

Diabetes Treatment and ManagementNitric Oxide and Endothelin Effects

Cited by 680

Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.

Näslund, E., Barkeling, B., King, N., Gutniak, M., Blundell, J., Holst, J., Rössner, S., & Hellström, P. (1999) · International Journal of Obesity

Regulation of Appetite and ObesityDiabetes Treatment and Management

Cited by 468

Inhibitory effect of glucagon-like peptide-1 on small bowel motility. Fasting but not fed motility inhibited via nitric oxide independently of insulin and somatostatin.

Tolessa, T., Gutniak, M., Holst, J. J., Efendic, S., & Hellström, P. M. (1998) · Journal of Clinical Investigation

Gastrointestinal motility and disordersNeuropeptides and Animal Physiology

Cited by 139

Effects of cholecystokinin (CCK)-8, CCK-33, and gastric inhibitory polypeptide (GIP) on basal and meal-stimulated pancreatic hormone secretion in man

Ahrén, B., Pettersson, M., Uvnäs-Moberg, K., Gutniak, M., & Efendic, S. (1991) · Diabetes Research and Clinical Practice

Pancreatic function and diabetesDiabetes Treatment and Management

Cited by 50